| [1] |
QIAO Meng, LEI Chao, CHEN Zijia, ZHANG Qiang, WANG Zhifei.
Analysis and thinking on the status quo of safety item information in the instructions of traditional Chinese patent medicines containing Asari Radix et Rhizoma and its extracts
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1401-1406.
|
| [2] |
MA Bingbing, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian, LYU Jintao.
Consideration of rational use of traditional Chinese medicine and pharmaceutical services for the elderly based on literature analysis
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 595-599.
|
| [3] |
ZHANG Ruili, SU Shuang, JIANG Jiming, ZHANG Jing.
Thirty-six cases of adverse drug reactions/events caused by Xinhuang tablets
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 561-563.
|
| [4] |
XIAO Wangzhong, LIN Cong, HUANG Li, DAI Bing, GAO Yuanfeng.
Contraindications in package inserts of Chinese patent medicine
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 400-403.
|
| [5] |
LI Ling, LIU Yanmei, TAN Jing, WANG Wen, YAO Minghong, MA Yu, LUO Xiaochao, LIAO Xing, LIU Yan, SONG Haibo, WEN Zehuai, SUN Xin.
Developing a safety assessment model for Chinese patent medicines based on real-world data
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 18-22.
|
| [6] |
LIAO Caiyun, LI Yiyun, YAO Wenbing, WEN Baoshu.
Dissemination Processes of the Chinese Orange Book: An Empirical Study
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 810-812.
|
| [7] |
ZHOU Sha, YANG Hongjun, JING Zhiwei, LI Geng.
Safety Information in Oral Chinese Patent Medicine Instructions for Big Brand Traditional Chinese Medicine
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 981-985.
|
| [8] |
ZHU Lan, Shao Bo, XIA Dongsheng.
Selection and Switch-to-OTC of Chinese Patent Medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 785-789.
|
| [9] |
WANG Yu,LIN Zhi-jian ,WANG Xiao, CHU Meng-zhen,ZHANG Bing.
Analysis and Pharmacovigilance Thinking on Chinese Patent Medicine Containing Psoraleae Fructus
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(5): 300-303.
|
| [10] |
JI Yue, WANG Tuo-ran, ZHANG Ke-xin, ZHOU Zi-jun, LIU Yu-xuan.
Literature Analysis of the Regularity and Adverse Reaction of Cinnamon and Its Prescription Preparations
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(3): 163-168.
|
| [11] |
CHEN Jie-feng1, LIU Tong1, HUANG Dan-ping2, HE Qi-di1, CHEN Zuan-guang1, YAO Mei-cun1, *.
Study on Developmental Toxicity of Four Chinese Patent Medicines to Zebrafish Embryos
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(4): 201-204.
|
| [12] |
YANG Qian, SUN Rong.
Summary and Analysis of Safety Warning on Clinical Application of Chinese Patent Medicine Preparations for Coronary Heart Disease
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(10): 602-605.
|
| [13] |
WANG Pei-jie, WANG Jia-lun, YI Zhi-wei, Dong Yan-fei, WANG Pu.
Literature Analysis of 40 Cases of Adverse Drug Reactions of Nonprescription Chinese Patent Medicines for Diseases of Throat Department
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(11): 690-692.
|
| [14] |
MA Ping, LI Peng-fei ,CAO Miao, DING Chun-lei ,WANG Yan, LIU Li-hong.
High Throughput and Rapid Screening for Illegally Added Chemicals in Chinese Patent Medicines and Health Products by LC-MS/MS
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(1): 19-21.
|
| [15] |
JI Yuan, SUN Hong-feng, ZHANG Li.
Safety Evaluation and Rational Use of Internal Application of OTC Chinese Patent Medicines for Orthopedics
[J]. Chinese Journal of Pharmacovigilance, 2011, 8(6): 352-355.
|
